Exact Sciences (EXAS) Competitors $45.60 +0.61 (+1.36%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$45.64 +0.04 (+0.09%) As of 08/15/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXAS vs. BIIB, INCY, UTHR, NBIX, BMRN, EXEL, MDGL, HALO, IONS, and RGENShould you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Exact Sciences vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Repligen Biogen (NASDAQ:BIIB) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Which has more risk and volatility, BIIB or EXAS? Biogen has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Do analysts recommend BIIB or EXAS? Biogen currently has a consensus target price of $185.74, indicating a potential upside of 34.01%. Exact Sciences has a consensus target price of $67.43, indicating a potential upside of 47.87%. Given Exact Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Exact Sciences is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Exact Sciences 0 Sell rating(s) 3 Hold rating(s) 20 Buy rating(s) 1 Strong Buy rating(s) 2.92 Do institutionals and insiders believe in BIIB or EXAS? 87.9% of Biogen shares are held by institutional investors. Comparatively, 88.8% of Exact Sciences shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 1.2% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is BIIB or EXAS more profitable? Biogen has a net margin of 15.31% compared to Exact Sciences' net margin of -34.19%. Biogen's return on equity of 13.85% beat Exact Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Exact Sciences -34.19%-1.75%-0.76% Does the media refer more to BIIB or EXAS? In the previous week, Biogen had 1 more articles in the media than Exact Sciences. MarketBeat recorded 38 mentions for Biogen and 37 mentions for Exact Sciences. Biogen's average media sentiment score of 0.96 beat Exact Sciences' score of 0.32 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 20 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Exact Sciences 12 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, BIIB or EXAS? Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$10.00B2.03$1.63B$10.4613.25Exact Sciences$2.94B2.94-$1.03B-$5.43-8.40 SummaryBiogen beats Exact Sciences on 9 of the 17 factors compared between the two stocks. Get Exact Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXAS vs. The Competition Export to ExcelMetricExact SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.52B$3.09B$5.66B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-8.4020.3830.5825.12Price / Sales2.94356.76462.42114.82Price / Cash7.9942.3037.4059.05Price / Book3.508.659.096.18Net Income-$1.03B-$54.65M$3.25B$264.89M7 Day Performance11.25%6.58%7.32%4.18%1 Month Performance-15.04%7.54%5.41%1.99%1 Year Performance-22.38%13.73%30.66%24.22% Exact Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXASExact Sciences4.8503 of 5 stars$45.60+1.4%$67.43+47.9%-22.0%$8.52B$2.94B-8.407,000News CoveragePositive NewsAnalyst ForecastBIIBBiogen4.8616 of 5 stars$128.00-2.0%$185.63+45.0%-31.3%$18.77B$9.68B12.247,605Analyst ForecastINCYIncyte4.6563 of 5 stars$79.19+1.0%$81.20+2.5%+40.9%$15.46B$4.24B18.002,617Trending NewsUTHRUnited Therapeutics4.915 of 5 stars$300.43-0.4%$379.69+26.4%-3.1%$13.55B$2.88B11.731,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.8566 of 5 stars$123.98-0.8%$160.90+29.8%-10.1%$12.30B$2.51B36.681,800Positive NewsBMRNBioMarin Pharmaceutical4.9979 of 5 stars$56.80-0.9%$93.17+64.0%-35.5%$10.91B$2.85B16.853,040Positive NewsEXELExelixis4.8805 of 5 stars$37.41-0.8%$44.44+18.8%+45.6%$10.07B$2.17B17.991,147Positive NewsAnalyst ForecastMDGLMadrigal Pharmaceuticals3.6889 of 5 stars$349.50+1.1%$430.43+23.2%+51.3%$7.76B$180.13M-27.2090Trending NewsAnalyst ForecastInsider TradeHALOHalozyme Therapeutics4.6141 of 5 stars$62.92+0.0%$66.56+5.8%+13.8%$7.75B$1.02B14.40390Positive NewsInsider TradeIONSIonis Pharmaceuticals4.4741 of 5 stars$40.84-1.9%$59.38+45.4%-6.2%$6.51B$944.05M-22.201,069Analyst UpgradeRGENRepligen4.8461 of 5 stars$111.88+0.4%$169.45+51.5%-23.5%$6.29B$673.96M-447.501,778Positive NewsInsider Trade Related Companies and Tools Related Companies Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives BioMarin Pharmaceutical Alternatives Exelixis Alternatives Madrigal Pharmaceuticals Alternatives Halozyme Therapeutics Alternatives Ionis Pharmaceuticals Alternatives Repligen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXAS) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access